Late hepatitis B reactivation following direct‐acting antiviral–based treatment of recurrent hepatitis C in an anti‐HBc–positive liver transplant recipient

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|67|2|791-793

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.67, Iss.2, 2018-02, pp. : 791-793

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct‐acting antiviral therapy for chronic hepatitis C: Data from a national US cohort

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 187-197

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal duration of pre‐liver transplantation anti‐hepatitis C virus treatment with direct‐acting agent sofosbuvir

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 6, 2015-06 ,pp. : 1776-1776

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐Effectiveness of New Direct‐Acting Antivirals to Prevent Post–Liver Transplant Recurrent Hepatitis

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 15, Iss. 7, 2015-07 ,pp. : 1817-1826

John Wiley & Sons Inc

Access to resources Recommend Favorite

The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1365-1372

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interferon‐free, direct‐acting antiviral therapy for chronic hepatitis C

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 1352-0504, Iss. 11, 2015-11 ,pp. : 861-870

John Wiley & Sons Inc

Access to resources Recommend Favorite